The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects

Jitendra Malviya; Arvind Parmar; Lokesh Parmar; Roshni Khan; Rituja Roy; Sushmita Kanade; Prince Giri; Balram Rathore

doi:doi:10.11648/j.ajbls.20210904.16

| Peer-Reviewed

The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects

Jitendra Malviya, Arvind Parmar, Lokesh Parmar, Roshni Khan, Rituja Roy, Sushmita Kanade, Prince Giri, Balram Rathore

Published in American Journal of Biomedical and Life Sciences (Volume 9, Issue 4)

Received: 6 June 2021 Accepted: 7 August 2021 Published: 31 August 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Since the outbreak of the novel corona virus disease COVID-19, precipitated by way of the SARS-CoV-2 virus, this sickness has unfolded hastily round the globe. Considering the practicable risk of a pandemic, scientists and medical doctors have been racing to apprehend this new virus and the pathophysiology of this disorder to discover feasible therapy regimens and find out fantastic therapeutic sellers and vaccines. To guide the cutting-edge lookup and development, CAS has produced a extraordinary record to furnish an overview of posted scientific statistics with an emphasis on patents in the CAS content material collection. It highlights antiviral techniques involving small molecules and biologics concentrated on complicated molecular interactions concerned in corona virus contamination and replication. The drug-repurposing effort documented herein focuses principally on dealers recognized to be superb in opposition to different RNA viruses such as SARS-CoV and MERS-CoV. The current secondary data have been chosen for the study while text 16 research articles to focus the study. The review is focus on that the challenges of coronaviruses and the new strains in Indian population due to constantly virus has changed through mutation appeared and disappeared too the more diverse and spread easily and resistant to treatments or vaccines. The vaccination in India is slow rate due to unavailability of the raw materials; the two Indian vaccine development companies have not able to provided vaccines as per the requirement. Unawareness has also been a biggest problem to the pandemic situation in the second wave of the coronavirus with new variants. The present study is deals with the challenges of new variants of coronavirus; the conditions of health system; Crisis of medicine, oxygen cylinder, failure of management increase more cases and finally the vaccination process; management and availability.

Published in	American Journal of Biomedical and Life Sciences (Volume 9, Issue 4)
DOI	10.11648/j.ajbls.20210904.16
Page(s)	219-229
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

SARSCOV-2 Antigen, Spike Protein, Covaxin, Covishield Vaccine

References

[1]	https://www.latimes.com/california/story/2021-04-06/double-mutant-coronavirus variant-found-California.
[2]	Yadav PD, Nyayanit DA, Sahay RR, et al. Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage. J Travel Med 2021; 28.
[3]	https://www.thehindu.com/news/national/pfizer-withdraws-emergency-use-authorisation-application-for-its-COVID-19-vaccine-in-india/article33757258.ece.
[4]	https://indianlekhak.com/india-news/in-the-endgame-of-the-epidemic-in-india-the-health-minister-says.
[5]	Sarah Cherian, Varsha Potdar, Santosh Jadhav, Pragya Yadav, Nivedita Gupta, Mousmi Das, Partha Rakshit, Sujeet Singh, Priya Abraham, Samiran Panda, NIC team. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Bio Rxiv 2021.04.22.440932.
[6]	Markus Hoffmann, Heike Hofmannwinkler, Nadine Krüger, Amy Kempf, Inga Neh meier, Luise Graichen, Anzhalika Sidarovich, Anna-Sophie Moldenhauer, Martin S. Winkler, Sebastian Schulz, Hans-Martin Jäck, Metodi V. Stankov, Georg M. N. Behrens, Stefan Pöhlmann. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Bio Rxiv 2021.05.04.442663.
[7]	Pragya D. Yadav, Sreelekshmy Mohandas, Anita M Shete, Dimpal Nyayanit, Nivedita Gupta, Deepak Y. Patil, GajanaN. Sapkal, Varsha Potdar, Manoj Kadam, Abhimanyu Kumar, Sanjay Kumar, Deepak Suryavanshi, Chandrashekhar S. Mote, Priya Abraham, Samiran Panda, Balram Bhargava. SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. Bio Rxiv 2021.05.05.442760.
[8]	Isabella Ferreira, Rawlings Datir, Guido Papa, Steven Kemp, Bo Meng, Partha Raksh, Sujeet Singh, Rajesh Pandey, Kalaiarasan Ponnusamy, V. S. Radhakrishnan. The Indian SARS-CoV-2 Genomics Consortium (INSACOG), The COVID-19 Genomics UK (COG-UK) consortium, Kei Sato, Leo James, Anurag Aggarwal, Ravindra K. Gupta. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. Bio Rxiv 2021.05.08.443253.
[9]	Yadav, P. D. et al. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab411 (2021).
[10]	www.thelancet.com Vol 397 May 8, 2021
[11]	www.thelancet.com Vol 397 May 1, 2021.
[12]	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00993-4/fulltext.
[13]	https://www.aljazeera.com/news/2021/4/27/indian-state-cracks-down-on-hospitals-flagging-oxygen-shortage.
[14]	https://www.bloomberg.com/news/articles/2021-04-29/how-india-s-vaccine-drive-crumbled-and-left-a-country-in-chaos.
[15]	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252125/pdf/main.pdf.

Cite This Article

Plain Text BibTeX RIS

APA Style

Jitendra Malviya, Arvind Parmar, Lokesh Parmar, Roshni Khan, Rituja Roy, et al. (2021). The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. American Journal of Biomedical and Life Sciences, 9(4), 219-229. https://doi.org/10.11648/j.ajbls.20210904.16

Copy | Download

ACS Style

Jitendra Malviya; Arvind Parmar; Lokesh Parmar; Roshni Khan; Rituja Roy, et al. The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. Am. J. Biomed. Life Sci. 2021, 9(4), 219-229. doi: 10.11648/j.ajbls.20210904.16

Copy | Download

AMA Style

Jitendra Malviya, Arvind Parmar, Lokesh Parmar, Roshni Khan, Rituja Roy, et al. The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. Am J Biomed Life Sci. 2021;9(4):219-229. doi: 10.11648/j.ajbls.20210904.16

Copy | Download

@article{10.11648/j.ajbls.20210904.16,
  author = {Jitendra Malviya and Arvind Parmar and Lokesh Parmar and Roshni Khan and Rituja Roy and Sushmita Kanade and Prince Giri and Balram Rathore},
  title = {The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {4},
  pages = {219-229},
  doi = {10.11648/j.ajbls.20210904.16},
  url = {https://doi.org/10.11648/j.ajbls.20210904.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210904.16},
  abstract = {Since the outbreak of the novel corona virus disease COVID-19, precipitated by way of the SARS-CoV-2 virus, this sickness has unfolded hastily round the globe. Considering the practicable risk of a pandemic, scientists and medical doctors have been racing to apprehend this new virus and the pathophysiology of this disorder to discover feasible therapy regimens and find out fantastic therapeutic sellers and vaccines. To guide the cutting-edge lookup and development, CAS has produced a extraordinary record to furnish an overview of posted scientific statistics with an emphasis on patents in the CAS content material collection. It highlights antiviral techniques involving small molecules and biologics concentrated on complicated molecular interactions concerned in corona virus contamination and replication. The drug-repurposing effort documented herein focuses principally on dealers recognized to be superb in opposition to different RNA viruses such as SARS-CoV and MERS-CoV. The current secondary data have been chosen for the study while text 16 research articles to focus the study. The review is focus on that the challenges of coronaviruses and the new strains in Indian population due to constantly virus has changed through mutation appeared and disappeared too the more diverse and spread easily and resistant to treatments or vaccines. The vaccination in India is slow rate due to unavailability of the raw materials; the two Indian vaccine development companies have not able to provided vaccines as per the requirement. Unawareness has also been a biggest problem to the pandemic situation in the second wave of the coronavirus with new variants. The present study is deals with the challenges of new variants of coronavirus; the conditions of health system; Crisis of medicine, oxygen cylinder, failure of management increase more cases and finally the vaccination process; management and availability.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects
AU  - Jitendra Malviya
AU  - Arvind Parmar
AU  - Lokesh Parmar
AU  - Roshni Khan
AU  - Rituja Roy
AU  - Sushmita Kanade
AU  - Prince Giri
AU  - Balram Rathore
Y1  - 2021/08/31
PY  - 2021
N1  - https://doi.org/10.11648/j.ajbls.20210904.16
DO  - 10.11648/j.ajbls.20210904.16
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 219
EP  - 229
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20210904.16
AB  - Since the outbreak of the novel corona virus disease COVID-19, precipitated by way of the SARS-CoV-2 virus, this sickness has unfolded hastily round the globe. Considering the practicable risk of a pandemic, scientists and medical doctors have been racing to apprehend this new virus and the pathophysiology of this disorder to discover feasible therapy regimens and find out fantastic therapeutic sellers and vaccines. To guide the cutting-edge lookup and development, CAS has produced a extraordinary record to furnish an overview of posted scientific statistics with an emphasis on patents in the CAS content material collection. It highlights antiviral techniques involving small molecules and biologics concentrated on complicated molecular interactions concerned in corona virus contamination and replication. The drug-repurposing effort documented herein focuses principally on dealers recognized to be superb in opposition to different RNA viruses such as SARS-CoV and MERS-CoV. The current secondary data have been chosen for the study while text 16 research articles to focus the study. The review is focus on that the challenges of coronaviruses and the new strains in Indian population due to constantly virus has changed through mutation appeared and disappeared too the more diverse and spread easily and resistant to treatments or vaccines. The vaccination in India is slow rate due to unavailability of the raw materials; the two Indian vaccine development companies have not able to provided vaccines as per the requirement. Unawareness has also been a biggest problem to the pandemic situation in the second wave of the coronavirus with new variants. The present study is deals with the challenges of new variants of coronavirus; the conditions of health system; Crisis of medicine, oxygen cylinder, failure of management increase more cases and finally the vaccination process; management and availability.
VL  - 9
IS  - 4
ER  -

Copy | Download

Author Information

Jitendra Malviya

Department of Life Sciences and Biological Sciences, IES University, Bhopal, India?
Arvind Parmar

Department of Pharmacy, Barkatullah University, Bhopal, India?
Lokesh Parmar

Department of Pharmacy, Barkatullah University, Bhopal, India?
Roshni Khan

Department of Pharmacy, Barkatullah University, Bhopal, India?
Rituja Roy

Department of Pharmacy, Barkatullah University, Bhopal, India?
Sushmita Kanade

Department of Pharmacy, Barkatullah University, Bhopal, India?
Prince Giri

Department of Pharmacy, Barkatullah University, Bhopal, India?
Balram Rathore

Department of Pharmacy, Barkatullah University, Bhopal, India?

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Jitendra Malviya, Arvind Parmar, Lokesh Parmar, Roshni Khan, Rituja Roy, et al. (2021). The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. American Journal of Biomedical and Life Sciences, 9(4), 219-229. https://doi.org/10.11648/j.ajbls.20210904.16

Copy | Download

ACS Style

Jitendra Malviya; Arvind Parmar; Lokesh Parmar; Roshni Khan; Rituja Roy, et al. The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. Am. J. Biomed. Life Sci. 2021, 9(4), 219-229. doi: 10.11648/j.ajbls.20210904.16

Copy | Download

AMA Style

Jitendra Malviya, Arvind Parmar, Lokesh Parmar, Roshni Khan, Rituja Roy, et al. The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects. Am J Biomed Life Sci. 2021;9(4):219-229. doi: 10.11648/j.ajbls.20210904.16

Copy | Download

@article{10.11648/j.ajbls.20210904.16,
  author = {Jitendra Malviya and Arvind Parmar and Lokesh Parmar and Roshni Khan and Rituja Roy and Sushmita Kanade and Prince Giri and Balram Rathore},
  title = {The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {4},
  pages = {219-229},
  doi = {10.11648/j.ajbls.20210904.16},
  url = {https://doi.org/10.11648/j.ajbls.20210904.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210904.16},
  abstract = {Since the outbreak of the novel corona virus disease COVID-19, precipitated by way of the SARS-CoV-2 virus, this sickness has unfolded hastily round the globe. Considering the practicable risk of a pandemic, scientists and medical doctors have been racing to apprehend this new virus and the pathophysiology of this disorder to discover feasible therapy regimens and find out fantastic therapeutic sellers and vaccines. To guide the cutting-edge lookup and development, CAS has produced a extraordinary record to furnish an overview of posted scientific statistics with an emphasis on patents in the CAS content material collection. It highlights antiviral techniques involving small molecules and biologics concentrated on complicated molecular interactions concerned in corona virus contamination and replication. The drug-repurposing effort documented herein focuses principally on dealers recognized to be superb in opposition to different RNA viruses such as SARS-CoV and MERS-CoV. The current secondary data have been chosen for the study while text 16 research articles to focus the study. The review is focus on that the challenges of coronaviruses and the new strains in Indian population due to constantly virus has changed through mutation appeared and disappeared too the more diverse and spread easily and resistant to treatments or vaccines. The vaccination in India is slow rate due to unavailability of the raw materials; the two Indian vaccine development companies have not able to provided vaccines as per the requirement. Unawareness has also been a biggest problem to the pandemic situation in the second wave of the coronavirus with new variants. The present study is deals with the challenges of new variants of coronavirus; the conditions of health system; Crisis of medicine, oxygen cylinder, failure of management increase more cases and finally the vaccination process; management and availability.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Challenges of Delta Variant of Coronavirus and Indian Vaccinations Can Envision the Coronavirus and Its Effects
AU  - Jitendra Malviya
AU  - Arvind Parmar
AU  - Lokesh Parmar
AU  - Roshni Khan
AU  - Rituja Roy
AU  - Sushmita Kanade
AU  - Prince Giri
AU  - Balram Rathore
Y1  - 2021/08/31
PY  - 2021
N1  - https://doi.org/10.11648/j.ajbls.20210904.16
DO  - 10.11648/j.ajbls.20210904.16
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 219
EP  - 229
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20210904.16
AB  - Since the outbreak of the novel corona virus disease COVID-19, precipitated by way of the SARS-CoV-2 virus, this sickness has unfolded hastily round the globe. Considering the practicable risk of a pandemic, scientists and medical doctors have been racing to apprehend this new virus and the pathophysiology of this disorder to discover feasible therapy regimens and find out fantastic therapeutic sellers and vaccines. To guide the cutting-edge lookup and development, CAS has produced a extraordinary record to furnish an overview of posted scientific statistics with an emphasis on patents in the CAS content material collection. It highlights antiviral techniques involving small molecules and biologics concentrated on complicated molecular interactions concerned in corona virus contamination and replication. The drug-repurposing effort documented herein focuses principally on dealers recognized to be superb in opposition to different RNA viruses such as SARS-CoV and MERS-CoV. The current secondary data have been chosen for the study while text 16 research articles to focus the study. The review is focus on that the challenges of coronaviruses and the new strains in Indian population due to constantly virus has changed through mutation appeared and disappeared too the more diverse and spread easily and resistant to treatments or vaccines. The vaccination in India is slow rate due to unavailability of the raw materials; the two Indian vaccine development companies have not able to provided vaccines as per the requirement. Unawareness has also been a biggest problem to the pandemic situation in the second wave of the coronavirus with new variants. The present study is deals with the challenges of new variants of coronavirus; the conditions of health system; Crisis of medicine, oxygen cylinder, failure of management increase more cases and finally the vaccination process; management and availability.
VL  - 9
IS  - 4
ER  -

Copy | Download